SVNS Stock Overview
Graft Polymer (UK) Plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Solvonis Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0016 |
| 52 Week High | UK£0.014 |
| 52 Week Low | UK£0.001 |
| Beta | 1.84 |
| 1 Month Change | -23.26% |
| 3 Month Change | 11.86% |
| 1 Year Change | -75.00% |
| 3 Year Change | -99.25% |
| 5 Year Change | n/a |
| Change since IPO | -99.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| SVNS | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | -13.2% | -4.8% | -0.9% |
| 1Y | -75.0% | -23.0% | 5.2% |
Return vs Industry: SVNS underperformed the UK Chemicals industry which returned -23% over the past year.
Return vs Market: SVNS underperformed the UK Market which returned 5.2% over the past year.
Price Volatility
| SVNS volatility | |
|---|---|
| SVNS Average Weekly Movement | 13.6% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SVNS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: SVNS's weekly volatility has decreased from 45% to 14% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 7 | Anthony Tennyson | www.graftpolymer.com |
Graft Polymer (UK) Plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds.
Solvonis Therapeutics plc Fundamentals Summary
| SVNS fundamental statistics | |
|---|---|
| Market cap | UK£3.79m |
| Earnings (TTM) | -UK£2.46m |
| Revenue (TTM) | UK£347.00k |
10.9x
P/S Ratio-1.5x
P/E RatioIs SVNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVNS income statement (TTM) | |
|---|---|
| Revenue | UK£347.00k |
| Cost of Revenue | UK£317.00k |
| Gross Profit | UK£30.00k |
| Other Expenses | UK£2.49m |
| Earnings | -UK£2.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0011 |
| Gross Margin | 8.65% |
| Net Profit Margin | -709.80% |
| Debt/Equity Ratio | 16.0% |
How did SVNS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/15 17:06 |
| End of Day Share Price | 2025/01/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solvonis Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|